Long-Term Safety of Semaglutide and Tirzepatide: 2025 Updates
Comprehensive review of long-term safety data for GLP-1 medications including side effects, risks, and 2025 Cochrane and regulatory updates.
More on Safety & Monitoring
Evidence Summary
This article synthesizes data from FDA safety databases, 2025 Cochrane systematic reviews, FAERS (FDA Adverse Event Reporting System), and published post-marketing surveillance studies for semaglutide and tirzepatide.
What We Know from Extended Studies
STEP Extension Studies (Semaglutide)
2-year follow-up data from STEP trials shows:
- Sustained weight loss in continued users (15.2% at 2 years)
- No increase in serious adverse events over time
- GI side effects generally improve with continued use
SURMOUNT Extension Studies (Tirzepatide)
18-month data from tirzepatide trials demonstrates:
- Peak weight loss at 72-88 weeks, then stabilization
- Similar safety profile to semaglutide
- Ongoing SURPASS-CVOT for cardiovascular outcomes
Key Safety Concerns and Current Evidence
Thyroid Cancer Risk
Animal Studies: Rodent studies showed thyroid C-cell tumors at high doses.
Human Data (2025): Post-marketing surveillance of 3+ million patients shows no statistically significant increase in thyroid cancer. The FDA boxed warning remains as a precaution.
Recommendation: Avoid in patients with personal/family history of medullary thyroid carcinoma or MEN2.
Pancreatitis
Incidence: ~0.3% in clinical trials, slightly elevated vs placebo.
2025 Update: Real-world data confirms low but real risk. Most cases are mild and resolve with discontinuation.
Recommendation: Stop medication and seek care for severe abdominal pain. Monitor high-risk patients.
Gallbladder Disease
Mechanism: Rapid weight loss increases cholesterol concentration in bile, promoting gallstone formation.
Incidence: 1.5-2.5% over 68 weeks, 2-3x higher than placebo.
Prevention: Adequate hydration, gradual dose titration, and ursodiol for high-risk patients.
Neuropsychiatric Effects (Under Investigation)
Emerging Signal: Reports of depression, anxiety, and suicidal ideation have prompted regulatory review.
2025 Status: EMA and FDA reviewing data. No causal link established; may be confounded by obesity-depression relationship.
Recommendation: Monitor mood changes, especially in patients with psychiatric history.
2025 Regulatory Updates
FDA Label Updates (2025)
- • Added warning about ileus/intestinal obstruction
- • Updated anesthesia guidance (stop 1-2 weeks before surgery)
- • Enhanced monitoring recommendations for kidney function
- • Updated drug interaction information
EMA Safety Committee Review
- • Ongoing review of suicidal ideation reports
- • No changes to benefit-risk assessment recommended
- • Enhanced pharmacovigilance activities initiated
Reassuring Safety Data
Cardiovascular Safety
SELECT trial (semaglutide) showed 20% reduction in major cardiovascular events. Far from harmful, GLP-1s appear cardioprotective.
Kidney Protection
FLOW trial demonstrated semaglutide reduces kidney disease progression by 24% in diabetic patients with CKD.
Frequently Asked Questions
Is it safe to take semaglutide or tirzepatide long-term?
Current evidence supports long-term use for most patients. Studies spanning 2-5 years show consistent safety profiles with no major new concerns emerging. However, ongoing monitoring is recommended, and risks should be weighed against benefits individually.
What are the main long-term concerns with GLP-1 medications?
Key concerns include thyroid C-cell tumors (observed in rodents, unclear human relevance), pancreatitis risk, gallbladder disease, and potential effects on bone density and muscle mass with rapid weight loss. Most serious events remain rare.
Has the FDA issued any new warnings for GLP-1s in 2025?
As of 2025, the FDA continues to monitor signals including ileus (intestinal blockage), aspiration risks during anesthesia, and potential psychiatric effects. No major new boxed warnings have been added, but prescribing information has been updated.
Should I get regular tests while on GLP-1 medications?
Regular monitoring is recommended including metabolic panels, kidney function, and for diabetic patients, HbA1c. Some providers recommend thyroid monitoring and periodic gallbladder evaluation for high-risk patients.
Get Safe, Monitored GLP-1 Treatment
Our medical team provides comprehensive monitoring and ongoing safety oversight for your GLP-1 therapy.
Start with Medical Supervision